Drugs Flashcards

1
Q

carboplatin MOA & AE

A

intrastrand DNA link

myelosuppression, infection susceptibility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

cyclophosphamide MOA & AE

A

inter- and intrastrand links

myelosuppression, hemorrhagic cystitis (give MENSA prophylatically)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

doxorubicin MOA & AE

A

intercalate, topo II inh, radicals

BM suppression, cardiotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

dactinomycin MOA & AE

A

intercalator, dna dependent rna syn inh

myelosuppression, hepatic dysfunction, infection susceptibility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

etoposide MOA & AE

A

topo II inhibitor

hematologic toxicity, BP instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ifosfamide MOA & AE

A

inter- and intrastrand links

BM suppression, hemorrhagic cystitis (give MENSA prophylatically)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

vincristine MOA & AE

A

blocks MT polymerization

neurotoxicity, “stocking glove”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

vHL mutation and RCC

A

VHL gene functions to mediate ub of HIF to send it to protease to be degraded (controlling mechanism)

w/ VHL mutation, no ub of HIF occurs so it can go on to activate EPO in hypoxic situations (such as new cell growth of tumors)

EPO–>VEGF activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

VEGF and RCC

A

target VEGF to stop angiogenesis needed for tumor growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

sequence of RCC therapy

A
  1. bevacizumab: Ab to VEGF
  2. -“nib”: TK inhibitor
  3. everolimus, temsirolimus: block mTOR

*TKI first then mTOR!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Rapamycins

A

Temsirolimus - weekly IV
Everolimus - daily oral

CYP substrates

bind to FKBP12 and inhibit mTORC1
(caveat: there is mTORC2 that actually promotes new cell growth but there is no drug to block that as of date)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TKIS

A

axitnib
sunitinib
sorafenib
pazopanib

significant CYP!

VEGFR TK Inhibitors

SE: CV: HTN, thromboembolism, hemorrhagic events, blood dyscrasias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

VEGF inh

A

bevacizumab - IV

thrombo, HTN, CHF, blood dyscrasias

BBW: hemorrhage, gi perfs, wound healing complications!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Immunotherapy IL-2

A

IL-2 (Aldesleukin) - activates JAK-STAT pathway to turn activate NK cells to kill cancer cells

MOA: IV 3 x week, max 14 dose

“controlled septic shock”
AE: hypotension, tachy, hematologic toxicity, renal toxcity
WATCH FOR SEPSIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Immunotherapy IFN-alpha

A

IFN-alpha 2 b - activates JAK-STAT to upreg genes for antiviral, antiproliferative, antitumor activities

AE: BBW - neuropsy, autoimmune, infectious dx

common - flu-like, leukopenia, neutropenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly